Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc is viewed positively due to its attractive current valuation, which, despite a reduction in the 12-month price target to $40 following a net present value analysis, suggests significant upside potential relative to the current share price. The company is focused on developing therapies that address serious autoimmune disorders, which are becoming increasingly relevant as evidenced by the rising incidence of idiopathic pulmonary fibrosis, with over 40,000 new cases diagnosed each year. Furthermore, GRI Bio’s unique product candidates, including GRI-0621 and GRI-0803, position the company favorably within the biotech sector, balancing high risks with substantial opportunities for growth.

Bears say

GRI Bio Inc reported a net loss of $3.9 million, equating to an earnings per share (EPS) of $(7.72), which fell short of both company estimates and consensus expectations. Significant concerns are raised regarding the company's liquidity and balance sheet, alongside multiple risks related to the clinical development of its product candidates, including the potential failure to demonstrate safety and efficacy, gain regulatory approval, or secure commercialization and reimbursement. Additionally, macroeconomic factors and shifting investor sentiment towards biotech investments further exacerbate the uncertainty surrounding GRI Bio's financial outlook.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.